Piñana, Jose LuisLopez-Corral, LuciaMartino, RodrigoMontoro, JuanVazquez, LourdesPerez, AriadnaMartin-Martin, GabrielFacal-Malvar, AnaFerrer, ElenaPascual, María-JesusSanz-Linares, GabrielaGago, BeatrizSanchez-Salinas, AndresVillalon, LuciaConesa-Garcia, VenancioOlave, Maria TLopez-Jimenez, JavierMarcos-Corrales, SaraGarcia-Blazquez, MartaGarcia-Gutierrez, ValentinHernandez-Rivas, Jose AngelSaus, AnaEspigado, IldefonsoAlonso, CarmenHernani, RafaelSolano, CarlosFerrer-Lores, BlancaGuerreiro, ManuelRuiz-Garcia, MontserratMuñoz-Bellido, Juan LuisNavarro, DavidCedillo, AngelSureda, Anna2023-05-032023-05-032021-12-08Piñana JL, López-Corral L, Martino R, Montoro J, Vazquez L, Pérez A, et al. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol. 2022 Jan 1;97(1):30-42http://hdl.handle.net/10668/19952This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia< 1 109/ml (odds ratio [OR] 0.33, 95% confidence interval [95% CI] 0.16–0.69, p = .003), active graft versus host disease (GvHD; OR 0.51, 95% CI 0.27–0.98, p = .04) and vaccination within the first year of transplant (OR 0.3, 95% CI 0.15–0.9, p = .04) associated with lower antibody detection whereas. In ASCT, non-Hodgkin's lymphoma (NHL; OR0.09, 95% CI 0.02–0.44, p = .003) and active corticosteroid therapy (OR 0.2, 95% CI 0.02–0.87, p = .03) were associated with lower detection rate. We report an encouraging rate of SARS-CoV-2-reactive antibodies detection in these severe immunocompromised patients. Lymphopenia, GvHD, the timing of vaccine, and NHL and corticosteroids therapy should be considered in allo-HSCT and ASCT, respectively, to identify candidates for SARS-CoV-2 antibodies monitoring.enAntibodies, ViralCOVID-19COVID-19 VaccinesHematopoietic Stem Cell TransplantationAdolescentAdultAgedFemaleHumansImmunocompromised HostMaleMiddle AgedProspective StudiesSARS-CoV-2SpainYoung Adultresearch article34695229Restricted AccessAnticuerposTrasplantesVacunaciónLinfopeniaHuésped inmunocomprometidoCélulas madre hematopoyéticas10.1002/ajh.263851096-8652PMC8646900https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.26385https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646900/pdf